No doubt there is a lot of frustration about communication and the lack of a deal to progress ATC, to date...
The frustration was expressed well from the floor.
The Board were clearly aware of such frustrations, and had come to the meeting to openly respond and Kirkwood did a good job of responding to most (not all) questions that they could answer, and avoiding the few where commercial in confidence was clearly an issue.
In comparison to last years AGM, where Coates didnt present, this year Coates came with an excellent presentation of where things are up to
Highlights? 1. the trial design to approval is spectacular... 2 week trial then conditional approval based on viral load decline already easily demonstrated in Phii with same design! 2. 17 year patent extension for atc and combo with potential partners drugs!
Make no mistake, ATC is a very good drug, will be approved, sell well and make a lot of money, but partnering is no simple and easy process...
but there is quite some confidence that the term sheets they have already received will turn into the right partner...soon...
AVX Price at posting:
4.0¢ Sentiment: LT Buy Disclosure: Held
